Numerous genetic variants have been studied in the context of antiplatelet responsiveness, particularly for aspirin and clopidogrel. The majority of these variants have failed to demonstrate any measurable level of clinical validity with the exception of the CYP2C19*2 allele. Several studies have identified a link between CYP2C19*2 carriers and decreased clopidogrel responsiveness as assessed by platelet reactivity testing and clinical outcomes. The FDA boxed warning and strong evidence of the CYP2C19*2 allele provide a compelling indication to alter treatment when genotype information is available. However, several questions remain and universal genotyping cannot be recommended at this time without further studies that establish the clinical utility of genomic testing for clopidogrel.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/138945011797635849 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-World Implementation of a Genotype-Guided P2Y Inhibitor De-Escalation Strategy in Acute Coronary Syndrome Patients.
JACC Cardiovasc Interv
July 2024
Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands; Department of Cardiology, University Medical Center Maastricht, Maastricht, the Netherlands.
Article Synopsis
- The study investigated whether using CYP2C19 genetic testing to guide medication choices improves outcomes for patients with acute coronary syndrome (ACS) compared to standard treatment.
- Out of 5,321 ACS patients, those who were genotyped and had their medications tailored showed significantly lower bleeding rates while maintaining a similar risk of ischemic events compared to those on standard therapy.
- The findings suggest that a personalized approach to antiplatelet therapy based on genetic markers can enhance safety without compromising efficacy in managing ACS.
Substantiation of a clopidogrel metabolism-associated gene (CYP2C19) variation among healthy individuals.
Indian Heart J
November 2023
Center of Excellence in Molecular Biology and Regenerative Medicine, Department of Biochemistry, JSS Medical College, JSS Academy of Higher Education & Research, Mysuru, India; Special Interest Group - Human Genomics and Rare Disorders, JSS Academy of Higher Education & Research, Mysuru, India. Electronic address:
Article Synopsis
- This study investigates the prevalence of CYP2C19 alleles, focusing on loss-of-function (LoF) alleles (CYP2C19∗2, CYP2C19∗3) and gain-of-function (GoF) alleles (CYP2C19∗17) in a population of 300 healthy adults.
- Researchers used allele-specific PCR to determine the frequencies of these alleles and the resulting metabolic phenotypes (ultra-rapid, extensive, intermediate, and poor metabolizers).
- Results showed a high frequency of poor metabolizers (12.67%) and recommended pre-treatment genotype testing to tailor drug dosages and reduce adverse effects.
Relationship between CYP2C19 Polymorphism and Clopidogrel Resistance in Patients with Coronary Heart Disease and Ischemic Stroke in China.
Genet Res (Camb)
November 2022
Department of Cardiology, Qinghai Provincial People's Hospital, Xining, Qinghai 810007, China.
Objective: Clopidogrel is widely used for preventing ischemic complications related to cardiovascular diseases. However, many patients experience clopidogrel resistance (CR). The polymorphisms of CYP2C19 have been implicated in CR, but CYP2C19 polymorphism considerably varies with both ethnic group and geographical location.
View Article and Find Full Text PDFGenetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer.
Front Pharmacol
June 2022
Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Anlotinib is a small molecular multi-targeting tyrosine kinase inhibitor. Growing evidence indicates that treatment efficacy, and toxicity varies considerably between individuals. Therefore, this study aimed to investigate the relationship between cytochrome P450 (CYP450) gene polymorphisms, drug concentrations, and their adverse reactions in anlotinib-treated patients with lung cancer.
View Article and Find Full Text PDFDoes CYP2C19 polymorphisms affect neurological deterioration in stroke/TIA patients?: A systematic review and meta-analysis of prospective cohort studies.
Medicine (Baltimore)
March 2021
Department of Information, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China.
Background: The association between cytochrome P450 2C19 (CYP2C19) polymorphisms and neurological deterioration in stroke or transient ischemic attack (TIA) patients is not completely understood. Hence, we performed a systematic review and meta-analysis of prospective cohort studies to quantify this association.
Methods: PubMed, Cochrane Library, Excerpta Medica Database, China National Knowledge Infrastructure and WanFang databases were searched for studies published up to April 2019.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!